ReviewWorld journal of gastroenterology2017
Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.
Review in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Corticosteroid Usage in Modeling Gulf War Illness in Pre-Clinical Models: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis.Journal of translational medicine · 2022Trial
- STING pathway contributes to Steroid-Hyporesponsive Lung Inflammation in DSS-induced colitis mice model.PloS one · 2026Article
- Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications.Clinical and experimental gastroenterology · 2026Article
- Integrative Machine Learning and Single-Cell RNA Sequencing Reveals Timp1+ Stromal Cells as Key Drivers in Ulcerative Colitis.Journal of inflammation research · 2026Article
- IgD-Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid-Induced Cell Death.European journal of immunology · 2026Article
- Apoptosis-related genes bridge inflammatory bowel disease and osteoporosis: A bioinformatic analysis.PloS one · 2026Article
- Engineered probiotics: a new era in treating inflammatory bowel disease.Journal of translational medicine · 2025Review
- Article
- Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.Journal of bacteriology · 2025Review
- Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease.Intestinal research · 2025Review
- Ginsenoside Rg2, a principal effective ingredient ofJournal of ginseng research · 2025Article
- Single and multiple switches, swap and retransitioning among 28,073 biological drug users with inflammatory bowel diseases: results from the Italian VALORE network.Therapeutic advances in gastroenterology · 2025Article
- Research advances in nanomaterials with aromatic functional groups for the treatment of inflammatory bowel disease.Frontiers in bioengineering and biotechnology · 2025Review
- Natural Product-based Therapies for Inflammatory Bowel Disease: Targeting Key Signaling Pathways.Mini reviews in medicinal chemistry · 2025Review
- Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review.Nutrients · 2024Review
- Neurobiological Implications of Chronic Stress and Metabolic Dysregulation in Inflammatory Bowel Diseases.Diseases (Basel, Switzerland) · 2024Review
- Challenges and opportunities in inflammatory bowel disease: from current therapeutic strategies to organoid-based models.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Cardiovascular risk assessment in inflammatory bowel disease with coronary calcium score.Annals of medicine and surgery (2012) · 2024Review
- Evaluating the causal effect of circulating proteome on the risk of inflammatory bowel disease-related traits using Mendelian randomization.Frontiers in immunology · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn's disease, are chronic pathologies associated with a deregulated immune response in the intestinal mucosa, and they are triggered by environmental factors in genetically susceptible individuals. Exogenous glucocorticoids (GCs) are widely used as anti-inflammatory therapy in IBDs. In the past, patients with moderate or severe states of inflammation received GCs as a first line therapy with an important effectiveness in terms of reduction of the disease activity and the induction of remission. However, this treatment often results in detrimental side effects. This downside drove the development of second generation GCs and more precise (non-systemic) drug-delivery methods. Recent clinical trials show that most of these new treatments have similar effectiveness to first generation GCs with fewer adverse effects. The remaining challenge in successful treatment of IBDs concerns the refractoriness and dependency that some patients encounter during GCs treatment. A deeper understanding of the molecular mechanisms underlying GC response is key to personalizing drug choice for IBDs patients to optimize their response to treatment. In this review, we examine the clinical characteristics of treatment with GCs, followed by an in depth analysis of the proposed molecular mechanisms involved in its resistance and dependence associated with IBDs. This thorough analysis of current clinical and biomedical literature may help guide physicians in determining a course of treatment for IBDs patients and identifies important areas needing further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.